Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Schering, A.g. Patentabteilung

Bayer Schering Pharma Ag

Dieter Bittler

Rudolf Wiechert

Henry Laurent

Klaus Nickisch

Wolfgang Losert

Yukishige Nishino

Jorge Casals-Stenzel

Rolf Bohlmann

Helmut Hofmeister

Gerhard Sauer

Ulrich Kerb

Martin Schneider

Rosemarie Lichtner

Nikolaus Heinrich

Karsten Parczyk

Manfred Albring

Annerose Schleusener

Walter Elger

Sybille Beier

Karl-Heinrich Fritzemeier

Josef Heindl

Christa Hegele-Hartung

Karl Petzoldt

Peter Esperling

Petra Rach

Klaus Prezewowsky

Hermann Kunzer

Ursula Habenicht

Horst Michna

Rudolf Weichert

Martin Haberey

Ekkehard Schillinger

Hans-Peter Muhn

Ulrike Fuhrmann

Hermann Kuenzer

Robert C Nickolson

Michael Topert

Jorg Kroll

Steffen Borden

Katja Prelle

Rainer Philippson

Bernhard Krieger

Peter Jungblut

Klaus Nickish

Christa Hegelehartung

Hermann K&uuml;nzer

A 18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactone of general formula I 

18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

This invention describes the new 7&agr;-(5-methylaminopentyl)-estratrienes of general formula I

7 &agr;-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7 &agr;(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents

This invention describes new, substituted 7&agr;-(&egr;-aminoalkyl)-estratrienes of general formula I

7&agr;-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7&agr;-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents

This invention describes new, substituted 7.alpha.-(.xi.-aminoalkyl)-estratrienes of general formula I ##STR1## in which side chain SK is a radical of partial formula ##STR2## as well as their physiologically compatible addition salts with organic and inorganic acids. The new compounds represent compounds with very strong antiestrogenic action. The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, antiestrogens with estrogenic partial action. Based on this spectrum of action, the new compounds are highly suitable for the production of pharmaceutical agents for tumor therapy and hormone replacement treatment.

7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production,

[3,2-c]Pyrazole and [3,2-d]triazole steroids are useful anti-androgens.

Antiandrogenic [3,2-c]pyrazole and [3,2-d]triazole steroids

Androstane derivatives of the general Formula I ##STR1## in which R.sub.1 represents a hydrogen atom or a methyl group,

Androstane derivatives

A pharmaceutical preparation for treating menopausal symptoms, estrogen deficiency and hormone-dependent tumors, and for use as a contraceptive, comprises a compound of formula I ##STR1## wherein R.sub.1 is hydrogen, methyl, a tetrahydropyranyl group or an acyl group and

17-methylene- and 17-ethylidene-estratrienes

17.alpha.-Alkyl steroids of the formula ##STR1## wherein R.sub.1 is hydrogen, acyl, alkyl, alkenyl, alkyl or alkenyl interrupted by an oxygen atom, cyclopentyl, or tetrahydropyranyl,

Antiandrogenic 17-alpha-alkyl steroids

2,2:6,6-diethylen-3-oxo-17alpha-pregn-4-ene-21,17alpha-carbolactones,

Dermatics utilizing 17.beta.methyl-18 nor steroids and methods for their

1.alpha.,7.alpha.-dithio-substituted spirolactones, processes for their

Estriol esters of Formula I ##STR1## wherein R is, in each case, the residue of an aliphatic monocarboxylic acid of 3-10 carbon atoms,

Estriol esters

Estriol esters of Formula I ##STR1## wherein R, in each case, means the residue of a monocarboxylic acid of 2-10 carbon atoms. The novel estriol esters surpass estriol in strength and duration of estrogen effect.

3,17 .beta.-estriol diesters, methods of their use, and pharmaceutical

Growing community of inventors

Berlin, Germany

Dieter Bittler